Cargando…
Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elmer Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635796/ https://www.ncbi.nlm.nih.gov/pubmed/36406194 http://dx.doi.org/10.14740/wjon1494 |
| _version_ | 1784824789218623488 |
|---|---|
| author | Xiang, Yi Lu, Xiao Juan Sun, Yi Hang Liu, Xia Wu, Yan Yang Rao, Hui Que, Qiu Yang Xiao, Qi Zhu, Rui Feng, Xiao Fei Lai, Wei Ling Zou, Xiao Huan Wang, Ying Qiu, Song Huang, Li Shi, Hua Qiu Wang, Xiang Cai |
| author_facet | Xiang, Yi Lu, Xiao Juan Sun, Yi Hang Liu, Xia Wu, Yan Yang Rao, Hui Que, Qiu Yang Xiao, Qi Zhu, Rui Feng, Xiao Fei Lai, Wei Ling Zou, Xiao Huan Wang, Ying Qiu, Song Huang, Li Shi, Hua Qiu Wang, Xiang Cai |
| author_sort | Xiang, Yi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9635796 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elmer Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96357962022-11-17 Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer Xiang, Yi Lu, Xiao Juan Sun, Yi Hang Liu, Xia Wu, Yan Yang Rao, Hui Que, Qiu Yang Xiao, Qi Zhu, Rui Feng, Xiao Fei Lai, Wei Ling Zou, Xiao Huan Wang, Ying Qiu, Song Huang, Li Shi, Hua Qiu Wang, Xiang Cai World J Oncol Letter to the Editor Elmer Press 2022-10 2022-10-22 /pmc/articles/PMC9635796/ /pubmed/36406194 http://dx.doi.org/10.14740/wjon1494 Text en Copyright 2022, Xiang et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor Xiang, Yi Lu, Xiao Juan Sun, Yi Hang Liu, Xia Wu, Yan Yang Rao, Hui Que, Qiu Yang Xiao, Qi Zhu, Rui Feng, Xiao Fei Lai, Wei Ling Zou, Xiao Huan Wang, Ying Qiu, Song Huang, Li Shi, Hua Qiu Wang, Xiang Cai Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer |
| title | Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer |
| title_full | Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer |
| title_fullStr | Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer |
| title_full_unstemmed | Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer |
| title_short | Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer |
| title_sort | precise therapeutic benefits and underlying mechanisms of anlotinib combined with checkpoint immunotherapy in advanced non-small-cell lung cancer |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635796/ https://www.ncbi.nlm.nih.gov/pubmed/36406194 http://dx.doi.org/10.14740/wjon1494 |
| work_keys_str_mv | AT xiangyi precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT luxiaojuan precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT sunyihang precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT liuxia precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT wuyanyang precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT raohui precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT queqiuyang precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT xiaoqi precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT zhurui precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT fengxiaofei precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT laiweiling precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT zouxiaohuan precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT wangying precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT qiusong precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT huangli precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT shihuaqiu precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer AT wangxiangcai precisetherapeuticbenefitsandunderlyingmechanismsofanlotinibcombinedwithcheckpointimmunotherapyinadvancednonsmallcelllungcancer |